Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397629 · ClinicalTrials.gov registry record
Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 62
- Enrollment target
NCT02397629: Completed study, sponsored by Wake Forest University Health Sciences.
NCT02397629 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02397629 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
Study Summary
This is a cross sectional study to examine the relationship between serum calcium and PTHrP and serum PSA in men referred for prostate biopsy at Wake Forest University.
Interventions
- OTHER This study has no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-05 |
What the finished NCT02397629 record still lists
NCT02397629 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 62 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which This study has no intervention is the first listed.
NCT02397629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02397629 about?
NCT02397629 is a clinical study titled "Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis". This is a cross sectional study to examine the relationship between serum calcium and PTHrP and serum PSA in men referred for prostate biopsy at Wake Forest University.
What is the current status of trial NCT02397629?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2013-05. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02397629?
The interventions under investigation include: This study has no intervention (OTHER).
Who is sponsoring clinical trial NCT02397629?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia